Eloxx Pharmaceuticals, Inc. – NASDAQ:ELOX
Eloxx Pharmaceuticals stock price today
Eloxx Pharmaceuticals stock price monthly change
Eloxx Pharmaceuticals stock price quarterly change
Eloxx Pharmaceuticals stock price yearly change
Eloxx Pharmaceuticals key metrics
Market Cap | 314 |
Enterprise value | 15.19M |
P/E | -0.39 |
EV/Sales | N/A |
EV/EBITDA | -0.27 |
Price/Sales | N/A |
Price/Book | -1.97 |
PEG ratio | N/A |
EPS | -9.07 |
Revenue | N/A |
EBITDA | -18.32M |
Income | -20.48M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEloxx Pharmaceuticals stock price history
Eloxx Pharmaceuticals stock forecast
Eloxx Pharmaceuticals financial statements
| Dec 2022 | 0 | -6.31M | |
|---|---|---|---|
| Mar 2023 | 0 | -6.23M | |
| Jun 2023 | 0 | -4.34M | |
| Sep 2023 | 0 | -3.59M |
| 2025 | 0 | -44.5M | |
|---|---|---|---|
| 2026 | 0 | -17.41M |
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 21123000 | 31.78M | 150.47% |
|---|---|---|---|
| Mar 2023 | 7200000 | 23.49M | 326.29% |
| Jun 2023 | 5993000 | 24.58M | 410.3% |
| Sep 2023 | 6042000 | 26.09M | 431.81% |
| Dec 2022 | -5.66M | 0 | 312K |
|---|---|---|---|
| Mar 2023 | -6.81M | 11K | -7.5M |
| Jun 2023 | -2.06M | 14K | 1.42M |
| Sep 2023 | -3.45M | 233K | 3.67M |
Eloxx Pharmaceuticals alternative data
| Aug 2023 | 18 |
|---|---|
| Sep 2023 | 18 |
| Oct 2023 | 18 |
| Nov 2023 | 18 |
| Dec 2023 | 18 |
| Jan 2024 | 18 |
| Feb 2024 | 18 |
| Mar 2024 | 18 |
| Apr 2024 | 18 |
| May 2024 | 18 |
| Jun 2024 | 18 |
| Jul 2024 | 18 |
Eloxx Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| May 2021 | 20244441 | 0 |
| Nov 2021 | 50000 | 0 |
| Quarter | Transcript |
|---|---|
| Q4 2020 11 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q2 2020 8 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q1 2020 11 May 2020 | Q1 2020 Earnings Call Transcript |
| Q4 2019 6 Mar 2020 | Q4 2019 Earnings Call Transcript |
-
What's the price of Eloxx Pharmaceuticals stock today?
One share of Eloxx Pharmaceuticals stock can currently be purchased for approximately $0.
-
When is Eloxx Pharmaceuticals's next earnings date?
Unfortunately, Eloxx Pharmaceuticals's (ELOX) next earnings date is currently unknown.
-
Does Eloxx Pharmaceuticals pay dividends?
No, Eloxx Pharmaceuticals does not pay dividends.
-
How much money does Eloxx Pharmaceuticals make?
Eloxx Pharmaceuticals has a market capitalization of 314.
-
What is Eloxx Pharmaceuticals's stock symbol?
Eloxx Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ELOX".
-
What is Eloxx Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Eloxx Pharmaceuticals?
Shares of Eloxx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Eloxx Pharmaceuticals have?
As Jul 2024, Eloxx Pharmaceuticals employs 18 workers.
-
When Eloxx Pharmaceuticals went public?
Eloxx Pharmaceuticals, Inc. is publicly traded company for more then 26 years since IPO on 26 Apr 1999.
-
What is Eloxx Pharmaceuticals's official website?
The official website for Eloxx Pharmaceuticals is eloxxpharma.com.
-
Where are Eloxx Pharmaceuticals's headquarters?
Eloxx Pharmaceuticals is headquartered at 480 Arsenal Way, Watertown, MA.
-
How can i contact Eloxx Pharmaceuticals?
Eloxx Pharmaceuticals's mailing address is 480 Arsenal Way, Watertown, MA and company can be reached via phone at +7 815775300.
Eloxx Pharmaceuticals company profile:
Eloxx Pharmaceuticals, Inc.
eloxxpharma.comNASDAQ
18
Biotechnology
Healthcare
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Watertown, MA 02472
CIK: 0001035354
ISIN: US29014R2022
CUSIP: 29014R103
